NZ Expands Vaccine Access as Pharmac Proposes Free Flu Shots for Young Children

Under the proposal, all children aged between six months and 59 months would become eligible for a funded influenza vaccine.

The New Zealand Government is moving to strengthen the country's immunisation programme with a major vaccine funding proposal that could significantly expand free flu vaccine access and improve protection for vulnerable groups across the country.

Associate Health Minister David Seymour has welcomed Pharmac's latest proposal, which includes funding free influenza vaccinations for children aged six months to under five years old, alongside broader changes to New Zealand's National Immunisation Schedule.

If approved, the proposal would make approximately 260,000 additional children eligible for funded flu vaccines from the 2027 influenza season.

The initiative forms part of a wider strategy aimed at improving public health outcomes, increasing vaccine protection, and ensuring long-term supply agreements for key vaccines used across New Zealand.

Expanded Protection for Children and Vulnerable Groups

Under the proposal, all children aged between six months and 59 months would become eligible for a funded influenza vaccine.

Health officials believe expanding access to flu vaccines for young children could help reduce hospitalisations, severe illness, and the spread of seasonal influenza within families and communities.

Minister Seymour said vaccines remain one of the most effective public health tools available and provide long-term value by preventing illness before it occurs.

"Vaccines are important to Kiwis and can provide good value if they stop people getting sick in the future," he said.

Pharmac estimates that more than 1.5 million New Zealanders would receive vaccines covered under the proposal during the first year alone if the plan is approved.

New Vaccine Brands Proposed

As part of the proposed changes, Pharmac is also considering introducing new vaccine brands for several immunisation programmes, including meningococcal ACWY, pneumococcal, and influenza vaccines.

According to the proposal, some of the newer vaccine brands could provide stronger protection for specific age groups and at-risk populations.

One of the most significant proposed changes involves the introduction of two innovative influenza vaccines specifically designed to offer increased protection for people aged 65 years and older, as well as vulnerable individuals under 65 who may be at greater risk of severe complications from influenza.

Officials say the updated pneumococcal vaccine brand could also improve coverage against additional strains of disease-causing bacteria, helping strengthen protection for vulnerable communities.

The Government believes these changes would modernise New Zealand's immunisation programme while aligning it with evolving international medical standards and scientific developments.

Expert Advice and Public Consultation

Before releasing the proposal, Pharmac sought advice from its Immunisation Advisory Committee, which provided expert clinical guidance on the proposed vaccine changes and supply arrangements.

Minister Seymour said public consultation remains an essential part of the decision-making process, ensuring community voices are included before final funding decisions are made.

"It's important to the patient community that their voice is heard," he said.

Pharmac officially opened public consultation on Thursday, 21 May, inviting feedback from healthcare professionals, consumer advocacy organisations, patients, and members of the public.

The consultation process is expected to help Pharmac evaluate both clinical recommendations and community concerns before determining whether the proposal will proceed.

The Government says this reflects a broader cultural shift within Pharmac toward more responsive and patient-focused decision-making.

"This is another example of the culture we are building at Pharmac — funding the medicines that Kiwis need, based on the feedback of Kiwis in need," Minister Seymour added.

Proposed Timeline for Rollout

If approved, the expanded influenza vaccine programme would begin from 1 April 2027.

The proposed changes involving meningococcal and pneumococcal vaccines, along with other vaccine supply agreements, would take effect from 1 July 2027.

Pharmac already has vaccine supply contracts in place covering the 2026 influenza season, meaning current immunisation programmes will continue unchanged in the meantime.

Health experts say early planning for vaccine supply agreements is critical to maintaining stable access to immunisations and ensuring New Zealand can respond effectively to seasonal disease outbreaks and future public health challenges.

Focus on Prevention and Long-Term Health

The proposal comes amid growing international focus on preventive healthcare and the role vaccinations play in reducing pressure on hospitals and healthcare systems.

Seasonal influenza remains a major health concern each year, particularly for young children, older adults, and individuals with underlying health conditions.

By widening free access and improving vaccine quality, the Government hopes to strengthen community immunity and reduce the long-term burden of preventable illnesses.

Pharmac is expected to review submissions from the consultation period before making a final decision on the proposal.